Johnson & Johnson drug shrinks tumors in early prostate cancer trial

A Johnson & Johnson prostate cancer drug shrank tumors in an early-stage trial.

The treatment is being tested for prostate cancer.

An early-stage trial is an initial test, so the result does not establish how well the drug works more broadly.

The available information does not state how many people took part or how much their tumors shrank.

The tumor response is an early sign of potential benefit, not proof that the drug is effective for patients generally.

Further trial results would be needed to judge its effects.